Tacalcitol (1,24-dihydroxyvitamin D3) is a synthetic
vitamin D3 analog.[1] Tacalcitol is marketed under several names, including Curatoderm and Bonalfa.
It is usually prescribed by a general practitioner or dermatologist for the treatment of
psoriasis, chronic
chapped lips and other severe dry skin conditions because of its ability to reduce excessive skin cell turnover.[1] It is available as an ointment or lotion.
^World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization.
hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
^Matsumoto K, Hashimoto K, Kiyoki M, Yamamoto M, Yoshikawa K (February 1990). "Effect of 1,24R-dihydroxyvitamin D3 on the growth of human keratinocytes". The Journal of Dermatology. 17 (2): 97–103.
doi:
10.1111/j.1346-8138.1990.tb03714.x.
PMID2158504.
S2CID38248260.
^Leone G, Pacifico A, Iacovelli P, Paro Vidolin A, Picardo M (March 2006). "Tacalcitol and narrow-band phototherapy in patients with vitiligo". Clin. Exp. Dermatol. 31 (2): 200–5.
doi:
10.1111/j.1365-2230.2005.02037.x.
PMID16487090.
S2CID39021489.
^Birlea SA, Costin GE, Norris DA (April 2008). "Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation". Current Drug Targets. 9 (4): 345–59.
doi:
10.2174/138945008783954970.
PMID18393827.
^Aoki T, Hashimoto H, Koseki S, Hozumi Y, Kondo S (November 1998). "1alpha,24-dihydroxyvitamin D3 (tacalcitol) is effective against Hailey-Hailey disease both in vivo and in vitro". Br. J. Dermatol. 139 (5): 897–901.
doi:
10.1046/j.1365-2133.1998.02522.x.
PMID9892963.
S2CID72418207.